This uses cookies that do not gather any personal information whatsoever. By using this website, you agree with the cookie policy.

António Abel Garcia Meliço-Silvestre

He is a Professor in the Faculty of Medicine of the University of Coimbra. Clinical Essays in Action: • RESIST 2 (Randomized Evaluation of Strategic Intervention in Multi-drug resistant patients with Tripanavir), Randomized, Open-Label, Comparative Safety and Efficacy Study of Tripanavir Boosted with Low Dose Ritonavir (TPV/RTV) versus Genotipically-Defined Protease Inhibitor/ Ritonavir (PI/RTV) in Multiple antirretroviral drug-experienced patients; • Multicentre, open-label pilot study to evaluate the efficacy and safety of HIVID (Zalcitabine DDC) BID regímen in Combination with zidovudine (ZDV) plus Protease Inhibitor (PI) and Lamivudine (3TC) plus zidovudine and PI in HIV-1 Infected Patients – AI 455-110; Radomised study, partially hidden, multicentric, third phase, with three arms, for the evaluation of the efficacy and safety of pegylated alfa-2a interferon in monotherapy versus combined alfa-2a interferon therapy with ribavirin during 48 weeks and 24 weeks of monitoring of cronic hepatitis C patients co-infected with the HIV virus • APV30005 – an open label phase III study to assess the long-term safety profile of GW433908 containing regimens in HIV1 infected subjects; • A phase III open-label safety study of T-20/RO29-9800 (HIV-1 fusion inhibitor) in combination with oral antiretrovirals, in patients who are unable to constract a viable regimen; • N.º CAL 30001: A Phase III, randomized, open-label, parallel, multicenter study to evaluate treatment with fixed dose combination of abacavir/lamivudine (600mg/300mg) once-daily versus abacavir (300mg) once daily in combination with tenofovir once daily and a new PI or NNRTI for 48 weeks in ART experienced HIV-1 infected patients; • AI424-900 – Atazanavir – (BMS-232632) for HIV – infected individuals: an early access program.